Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

164.17 +1.87 (+1.15%)
Streaming Delayed Price Updated: 3:01 PM EST, Feb 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN)
From Brodsky & Smith LLC
Via GlobeNewswire
3 Dividend Stocks to Buy Now for Lifelong Income
Here are three dividend stocks to buy now offering stability, growth, and lifelong income in the pharmaceutical and tobacco industries. 
Via InvestorPlace
5 Crash-Proof Stocks to Buy Immediately
We may not be headed to a full-blown crisis, but savvy investors should protect their portfolios now with these crash-proof stocks. 
Via InvestorPlace
3 Dividend Kings Down 11% You’ll Regret Not Buying on the Dip
These dividend stocks have proved time and again why they're the cream of the crop and will rise to the top once more. 
Via InvestorPlace
Unpacking the Latest Options Trading Trends in Johnson & Johnson
Via Benzinga
MarketBeat Week in Review – 4/15 - 4/19
The markets continued to move lower ahead of a big earnings week as analysts adjust valuations on the outlook for interest rates and geopolitical concerns 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Investing for the Long-Term: 3 Stocks With Proven Track Records
As uncertainty in the global economy and geopolitical climate abounds, investors should focus on stocks with proven track records. 
Via InvestorPlace
Topics Economy
Exposures Economy
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game. 
Via InvestorPlace
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
The Nasdaq and S&P 500 tumbled below their 50-day lines. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory... 
Via Benzinga
Topics Brexit
Exposures Brexit
Johnson & Johnson Children's Cough Syrup Contaminated In Some Batches - WHO Poised to Issue Global Alert
WHO alerts the global community about tainted children's cough syrup by Johnson & Johnson. Elevated toxin levels detected in Benylin syrup prompt recalls across Africa. Investigation is underway. 
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
Exposures Product Safety
Top Stock Reports For Nvidia, Alphabet And Johnson & Johnson
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ). 
Via Talk Markets
Recession-Proof Riches: 3 Stocks That Thrive in Any Economy
Discover recession-proof stocks that thrive amid economic uncertainty, offering stability and consistent growth. 
Via InvestorPlace
Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.
Investors wondering which tax refund stocks to invest in should consider these names, each of which is a capital compounder. 
Via InvestorPlace
Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future
Johnson & Johnson reports first-quarter earnings, with adjusted EPS up 12.4% and sales up 2.3%. Analysts optimistic about stock's future, highlighting potential growth from new drug approvals. JNJ aims... 
Via Benzinga
Johnson & Johnson Analysts Cut Their Forecasts After Q1 Results
Johnson & Johnson (NYSE: JNJ) reported better-than-expected first-quarter earnings on Tuesday. 
Via Benzinga
Invest Like a Hawk: 7 Stocks to Own If the Fed Stays Tough
Although monetary policy seemed to be moving in a dovish direction, a pivot may warrant a look at stocks for Fed hikes. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Put $10,000 in These 3 Dividend Stocks by 2025
In market uncertainty, dividend stocks come to the rescue. Rebalance your portfolio with these three dividend stocks and enjoy steady income. 
Via InvestorPlace
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Johnson & Johnson's Q1 2024 earnings offer a mixed picture of resilience amidst economic headwinds and provide insight into the broader medtech sector's health. 
Via MarketBeat
Topics Economy
Exposures COVID-19 Supply Chain
Why Johnson & Johnson Stock Got Tossed by the Market Today
A mixed quarter and narrowed guidance didn't really please investors. 
Via The Motley Fool
Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript
JNJ earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Grapple With Geopolitical Pressures, Gold Eyes $2,400, Bitcoin Falls Below $62,000: What's Driving Markets Tuesday?
Investors remain on edge as geopolitics continue to shape market trends, with Israel mulling a response to Iran while the U.S. and key allies explore further sanctions against Tehran. 
Via Benzinga
Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff
On Tuesday, Johnson & Johnson (NYSE: JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost... 
Via Benzinga
JNJ Stock Earnings: Johnson & Johnson Beats EPS, Misses Revenue for Q1 2024
JNJ stock results show that Johnson & Johnson beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Q1 Earnings Tops Wall Street Estimates On Strong Medical Devices Sales, Boosts Annual Outlook
Johnson & Johnson reports Q1 results: adjusted EPS $2.71 (up 12.4% Y/Y), sales $21.38B (up 2.3% Y/Y). Explore pharma giant's robust performance, including strong growth in Innovative Medicine and... 
Via Benzinga
Johnson & Johnson is as Cheap as it’s Going to Get
Johnson & Johnson raised its dividend for the 62nd consecutive year and has the power to continue raising the annual payout indefinitely. 
Via MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN)
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.